505(b)(1)

LXP103

Aligning with global metabolic health trends, LXP103 addresses complex metabolic dysregulations. The core advantage lies in balancing metabolic improvement with physiological stability. By offering a precise and gentle alternative to conventional therapies, this new chemical entity represents a shift toward holistic health management with significant differentiation.

Therapeutic Area:

Metabolic Disorders

Development Value

As global metabolic health awareness rises, market focus is shifting from simple weight loss to holistic management centered on physiological maintenance and long-term stability. Our innovative molecule, LXP103, is being developed as a systemic regulatory candidate, focusing on a unique mechanism to support physiological balance. It aims to provide a stable, safe, and sustainable long-term management solution for populations facing metabolic dysregulation.

Latest Progress

Development Stage

Preclinical

IND

Phase I

Phase II

Phase III

NDA

Preclinical

Patents

Patents have been granted in Taiwan and the United States, with applications filed in other countries still in progress.